Fairvalue-Calculator Fairvalue-Calculator
EN DE

Silence Therapeutics plc (SLN) Fair Value & Analysis

Healthcare · US · Market cap $356M

Price$7.27
Fair Value$5.94
Upside-18.3%
Quality95/100
Evidence: Low Range $4.45 – $7.42

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Silence Therapeutics plc (SLN) currently trades at $7.27, while our model-based Fair Value estimate is $5.94 — implying the stock looks roughly 18.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Silence Therapeutics plc (SLN) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $5.94 versus a price of $7.27 — about −18% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SLN?
Our 21-model fair value for Silence Therapeutics plc is $5.94 (as of Jun 24, 2026), built from audited fundamentals. The current price is $7.27.
What is the quality score of SLN?
Silence Therapeutics plc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.